IN8bio to Present at Upcoming Investor Conferences
26 Febrero 2024 - 7:00AM
Business Wire
IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage
biopharmaceutical company focused on innovative gamma-delta T cell
therapies, today announced that William Ho, CEO and Co-founder,
will present at the following investor conferences in March:
TD Cowen 44th Annual Health Care Conference Company
presentation Monday, March 4, 2024, at 9:50 am ET
2nd Annual H.C. Wainwright Cell Therapy Virtual
Conference Virtual company presentation Tuesday, March 26,
2024
A live webcast and replay will be available under "Events and
Presentations" in the News & Presentations section of the
IN8bio website at https://investors.in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of gamma-delta T
cell product candidates for solid and liquid tumors. Gamma-delta T
cells are a specialized population of T cells that possess unique
properties, including the ability to differentiate between healthy
and diseased tissue. IN8bio’s DeltEx platform employs allogenic,
autologous, iPSC and genetically modified approaches to develop
cell therapies, designed to effectively identify and eradicate
tumor cells.
IN8bio has initiated a Phase 2 trial of INB-400 in GBM in the
United States and has two ongoing Phase 1 trials in solid and
hematologic tumors, including INB-200 for GBM and INB-100 for
patients with hematologic malignancies undergoing transplantation.
IN8bio also has a broad portfolio of preclinical programs focused
on addressing other hematological and solid tumor cancers. For more
information visit www.IN8bio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240226996465/en/
Company Contact IN8bio, Inc. Patrick McCall +1
646.600.6GDT (6438) info@IN8bio.com
Investors Meru Advisors Lee M. Stern
lstern@meruadvisors.com
Media Contact Kimberly Ha KKH Advisors 917.291.5744
kimberly.ha@kkhadvisors.com
IN8bio (NASDAQ:INAB)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
IN8bio (NASDAQ:INAB)
Gráfica de Acción Histórica
De May 2023 a May 2024